Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2866)	6/1/2010 3:25:00 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ONCY is up for 4th day on a roll as it trades above the resistance at the $3 level and above its May Hs. The next resistance is now the Aprl 8 H at $3.30 before it can try to test its March 12 H at $3.63 <g> bigcharts.marketwatch.com ONCY has been trimming some its losses in the last 4Qs. It announced today that it has received approval from the Belgian AMHP to conduct its PIII examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by the FDA under the SPA ONCY said that obtaining approval to conduct this trial in Belgium will allow them to expand European enrollment and to access leading head and neck specialists.<g> The primary endpoint for the trial is overall survival. The decision to pursue a PIII in head and neck cancers was predicated on positive results seen in the PI & PII of the combination REOLYSIN and paclitaxel/carboplatin The ACTAY is only $2 ONCY will need some good news to be able to make it to the $4 level.<g> bigcharts.marketwatch.com Bernard